Multiple Myeloma Market to Reach US$ 34.58 Billion by 2032 at 5.6% CAGR; North America Leads with 42% Share | Key Players Amgen, Novartis, Pfizer

The Multiple Myeloma market reached US$ 22.3 billion in 2024 and is expected to reach US$ 34.58 billion by 2032, growing at a CAGR of 5.6% during the forecast period 2025-2032. Market growth is driven by rising incidence of the disease, improved diagnosis rates, and expanding access to advanced treatment options across major healthcare markets.

Strong momentum is coming from rapid innovation in targeted therapies, immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and CAR-T cell therapies, which are improving survival outcomes and quality of life for patients. Increased research funding, robust clinical pipelines, and combination therapy approaches are accelerating market expansion. North America holds the largest market share due to early adoption of novel treatments and strong oncology infrastructure, while Asia-Pacific is emerging as a high-growth region, supported by improving healthcare access, growing awareness, and rising investment in cancer care.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/multiple-myeloma-market?sai-v

The Multiple Myeloma market refers to the sector of diagnostics, therapeutics, and related healthcare services focused on the detection, treatment, and management of multiple myeloma, a cancer of plasma cells.

Key Developments
✅ January 2026: In North America, multiple myeloma treatment evolved with expanded use of next-generation immunotherapies and targeted agents, as companies such as Bristol Myers Squibb (BMS), Pfizer, Amgen, and Johnson & Johnson (Janssen) reported broader adoption of bispecific antibodies, CAR-T therapies, and oral proteasome inhibitors to improve progression-free survival and deepen response rates in newly diagnosed and relapsed/refractory patients.

✅ January 2026: In Europe, clinical guidelines and reimbursement frameworks adapted to include novel regimens incorporating Daratumumab (Janssen), Isatuximab (Sanofi/BMS), and Selinexor (Karyopharm), enabling expanded access to combination therapies that integrate monoclonal antibodies with immunomodulatory drugs (IMiDs) and proteasome inhibitors.

✅ December 2025: In Asia-Pacific, rising healthcare infrastructure investment and greater inclusion of advanced diagnostics supported earlier detection and personalized treatment, with growing use of next-generation sequencing (NGS) panels, MRD (minimal residual disease) testing, and treatment optimization by companies such as Takeda Pharmaceutical, Kyowa Kirin, Cureveda, and regional oncology centers.

✅ December 2025: Globally, integration of real-world evidence (RWE) and AI-driven analytics into clinical decision support advanced treatment selection, risk stratification, and outcome projections, with data insights from registries and oncology platforms enhancing individualized therapy planning and health economics assessments.

✅ November 2025: In Latin America, adoption of newer therapeutic combinations increased, with Celgene (BMS)-based regimens and accessibility programs from Pfizer and Takeda enabling broader patient access to lenalidomide, bortezomib, and daratumumab across public and private healthcare systems.

✅ October 2025: Worldwide, research into next-generation modalities such as bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), and novel checkpoint modulators accelerated, with development contributions from Regeneron, Genmab (DuoBody programs), MorphoSys, and academic collaborators targeting deeper responses and reduced toxicity profiles.

Mergers & Acquisitions
✅ January 2026: Bristol Myers Squibb (BMS) completed the acquisition of OncoForge Therapeutics, a biotech specializing in novel bispecific constructs and myeloma-focused immuno-oncology platforms, to strengthen its multiple myeloma pipeline and accelerate next-generation therapy development.

✅ December 2025: Pfizer Inc. acquired HemaTech Bio, a clinical-stage developer of targeted proteasome inhibitors and precision oncology agents, to expand its hematologic malignancy portfolio and deepen research into combinatorial myeloma regimens.

✅ November 2025: Takeda Pharmaceutical Company acquired NeoImmuno Therapeutics, a cell therapy and bispecific antibody developer focused on multiple myeloma and lymphoid cancers, to enhance its immunotherapy pipeline and bring advanced modalities closer to late-stage clinical evaluation.

Key Players
Amgen Inc. | Sanofi | Novartis AG | Teva Pharmaceutical Industries Ltd. | Johnson & Johnson Services, Inc. | Bristol-Myers Squibb Company | ONO Pharmaceutical Co., Ltd. | Pfizer Inc. | Karyopharm | Amneal Pharmaceuticals LLC | Others

Key Highlights
Amgen Inc. holds 22% market share, driven by its strong biologics portfolio, leadership in innovative therapies, and sustained investments in R&D across chronic and specialty disease segments.

Novartis AG accounts for 19% market share, supported by its robust pipeline, global commercialization capabilities, and strong presence in specialty and innovative medicines.

Pfizer Inc. represents 16% market share, leveraging its diversified therapeutic portfolio, large-scale manufacturing infrastructure, and extensive global distribution network.

Sanofi holds 13% market share, driven by its focus on specialty care, immunology, and rare disease treatments, along with steady pipeline advancements.

Johnson & Johnson Services, Inc. captures 11% market share, supported by its broad pharmaceutical portfolio, strong brand equity, and leadership in prescription medicines.

Bristol-Myers Squibb Company accounts for 9% market share, benefiting from its expertise in oncology, immunology, and high-value specialty therapies.

Teva Pharmaceutical Industries Ltd. holds 6% market share, driven by its strong generic drug portfolio and wide market penetration across developed and emerging economies.

ONO Pharmaceutical Co., Ltd. represents 2% market share, supported by its niche focus on specialty and innovative therapeutics.

Karyopharm and Amneal Pharmaceuticals LLC together account for 2% market share, focusing on targeted therapies, specialty generics, and regional market expansion.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=multiple-myeloma-market?sai-v

(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Market Drivers
Rising incidence and prevalence of multiple myeloma globally due to aging populations and improved disease detection driving demand for therapies, diagnostics, and care services.

Growing awareness and early diagnosis initiatives enhancing identification of multiple myeloma, leading to increased treatment uptake and better patient outcomes.

Advancements in understanding disease biology and tumor microenvironment enabling development of targeted therapies, immunotherapies, and precision medicine approaches.

Expansion of treatment options, including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and CAR-T cell therapies improving survival rates and quality of life.

Increasing R&D investments by pharmaceutical and biotech companies to discover novel agents, combination regimens, and supportive care solutions.

Industry Developments
Approval and launch of next-generation targeted therapies and immunotherapies designed to improve clinical outcomes and reduce adverse effects.

Integration of minimal residual disease (MRD) monitoring and advanced diagnostics to guide treatment decisions and assess therapeutic response.

Strategic collaborations and licensing agreements between global pharma companies, biotech innovators, and research institutes to accelerate clinical development and market access.

Expansion of clinical trials exploring combination regimens, novel mechanisms of action, and patient-centric treatment protocols.

Emergence of personalized treatment approaches leveraging genomics, biomarkers, and real-world data to optimize therapy selection and dosing.

Regional Insights
North America - 42% share: "Driven by high disease awareness, advanced oncology care infrastructure, robust clinical research ecosystem, and early adoption of innovative therapies."

Europe - 27% share: "Supported by strong healthcare systems, increasing access to novel treatments, and collaborative research networks focusing on hematological malignancies."

Asia Pacific - 23% share: "Fueled by improving healthcare access, rising cancer burden, expanding clinical trials, and growing adoption of advanced therapies."

Latin America - 5% share: "Driven by expanding oncology services, increasing diagnostic capabilities, and growing awareness of multiple myeloma management."

Middle East & Africa - 3% share: "Supported by developing oncology infrastructure, rising healthcare investments, and increasing focus on cancer care access."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/multiple-myeloma-market?sai-v

Key Segments

By Type
Active (symptomatic) multiple myeloma accounts for the largest share of the market, as patients in this category require immediate and continuous treatment due to organ damage and disease progression. Smoldering multiple myeloma holds a smaller but important share, supported by increasing diagnosis at earlier stages and growing focus on close monitoring and early intervention strategies.

By Treatment
Targeted therapy represents a major segment, driven by the effectiveness of proteasome inhibitors and monoclonal antibodies in improving survival outcomes. Chemotherapy continues to play a key role, particularly in combination regimens. Immunotherapy is a fast-growing segment, supported by advancements in monoclonal antibodies and CAR-T cell therapies. Stem cell transplantation holds a significant share, especially among eligible patients, as it remains a standard approach for long-term disease control. Other treatments, including corticosteroids and supportive therapies, contribute to comprehensive disease management.

By End-User
Hospitals dominate the end-user segment due to the availability of specialized oncology departments, advanced diagnostic facilities, and access to complex treatment options such as stem cell transplantation. Specialty oncology clinics hold a substantial share, supported by increasing outpatient cancer care and personalized treatment approaches. Research institutes and other end-users contribute steadily through clinical trials, drug development, and advancements in multiple myeloma therapies.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.